Cardiovascular adverse events associated with smoking-cessation pharmacotherapies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Current Science Country of Publication: United States NLM ID: 100888969 Publication Model: Print Cited Medium: Internet ISSN: 1534-3170 (Electronic) Linking ISSN: 15233782 NLM ISO Abbreviation: Curr Cardiol Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : Current Science, c1999-
    • Subject Terms:
      Smoking Prevention*; Benzazepines/*adverse effects ; Bupropion/*adverse effects ; Nicotinic Agonists/*adverse effects ; Quinoxalines/*adverse effects ; Smoking Cessation/*methods; Benzazepines/administration & dosage ; Bupropion/administration & dosage ; Chest Pain/chemically induced ; Dose-Response Relationship, Drug ; Humans ; Hypertension/chemically induced ; Nicotinic Agonists/administration & dosage ; Practice Guidelines as Topic ; Quinoxalines/administration & dosage ; Randomized Controlled Trials as Topic ; Seizures/chemically induced ; Tachycardia/chemically induced ; Varenicline
    • Abstract:
      Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.
    • References:
      Am J Psychiatry. 1991 Apr;148(4):512-6. (PMID: 1900980)
      Eur J Clin Pharmacol. 1995;47(5):411-6. (PMID: 7720762)
      Addiction. 2013 Oct;108(10):1711-21. (PMID: 23834141)
      N Engl J Med. 1996 Dec 12;335(24):1792-8. (PMID: 8943160)
      JAMA Intern Med. 2013 May 13;173(9):817-9. (PMID: 23529063)
      J Am Coll Cardiol. 2004 Aug 4;44(3):671-719. (PMID: 15358045)
      CMAJ. 2011 Sep 6;183(12):1359-66. (PMID: 21727225)
      Eur Heart J. 1993 Dec;14(12):1709-11. (PMID: 8131771)
      Tob Induc Dis. 2010 Jul 13;8:8. (PMID: 20626883)
      Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):91-111. (PMID: 12920702)
      Circulation. 2014 Jan 7;129(1):28-41. (PMID: 24323793)
      J Neurophysiol. 2003 May;89(5):2473-81. (PMID: 12611951)
      Thromb Haemost. 1997 Sep;78(3):1093-6. (PMID: 9308759)
      Am J Med. 2006 Dec;119(12):1080-7. (PMID: 17145253)
      Nicotine Tob Res. 2003 Apr;5(2):195-203. (PMID: 12745492)
      Cardiovasc Drugs Ther. 1998 Jul;12(3):239-44. (PMID: 9784902)
      Am Heart J. 2000 Oct;140(4 Suppl):84-8. (PMID: 11011353)
      Lancet. 2012 Mar 31;379(9822):1269-71. (PMID: 21963004)
      J Cardiovasc Pharmacol. 1999 Nov;34(5):694-9. (PMID: 10547086)
      Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. (PMID: 21328282)
      Drugs. 1992 Sep;44(3):498-529. (PMID: 1382940)
      Drug Saf. 1999 Jun;20(6):545-55. (PMID: 10392670)
      Arq Bras Cardiol. 2007 Apr;88(4):434-40. (PMID: 17546274)
      J Am Coll Cardiol. 1997 Jul;30(1):125-30. (PMID: 9207632)
      BMJ. 2012 Nov 08;345:e7176. (PMID: 23138033)
      Drug Saf. 2008;31(11):1017-26. (PMID: 18840021)
      Drug Saf. 1998 Apr;18(4):297-308. (PMID: 9565740)
      Can J Cardiol. 1997 May;13(5):525-8. (PMID: 9179092)
      Ann Pharmacother. 1994 Mar;28(3):402. (PMID: 8193434)
      Am J Med. 1996 Oct;101(4):357-63. (PMID: 8873505)
      Chest. 1995 Jun;107(6):1765-6. (PMID: 7781384)
      JAMA. 1994 Jun 22-29;271(24):1940-7. (PMID: 8201739)
      Lancet. 1995 Sep 16;346(8977):777-8. (PMID: 7658896)
      Circulation. 2010 Jan 19;121(2):221-9. (PMID: 20048210)
      Arch Intern Med. 1994 May 9;154(9):989-95. (PMID: 8179456)
      Respiration. 1985;48(3):237-44. (PMID: 4070801)
      J Am Coll Cardiol. 2001 Apr;37(5):1297-302. (PMID: 11300438)
      J Cardiovasc Pharmacol. 1998 May;31(5):714-20. (PMID: 9593071)
      Ann Intern Med. 1994 Apr 15;120(8):695. (PMID: 8135462)
      Am J Med Sci. 2003 Oct;326(4):183-6. (PMID: 14557731)
      Eur Heart J. 2003 May;24(10):946-55. (PMID: 12714026)
      Auton Neurosci. 2011 Oct 28;164(1-2):82-6. (PMID: 21664880)
      Arch Intern Med. 2000 Apr 10;160(7):939-44. (PMID: 10761958)
      Drug Saf. 2012 Jan 1;35(1):33-43. (PMID: 22149418)
      N Engl J Med. 2013 Jan 24;368(4):341-50. (PMID: 23343063)
      QJM. 2001 Sep;94(9):503-4. (PMID: 11528015)
      Neuropharmacology. 2007 Mar;52(3):985-94. (PMID: 17157884)
      Clin Pharmacol Ther. 1998 Jul;64(1):87-95. (PMID: 9695723)
      CNS Drugs. 2001;15(5):391-411. (PMID: 11475944)
      Mayo Clin Proc. 2005 May;80(5):652-6. (PMID: 15887433)
      J Am Coll Cardiol. 1993 Oct;22(4):1159-67. (PMID: 7691912)
      Thorax. 2013 Nov;68(11):1037-42. (PMID: 23404838)
      Br J Dermatol. 1996 Feb;134(2):361-4. (PMID: 8746358)
      Am J Prev Med. 2008 Aug;35(2):158-76. (PMID: 18617085)
      BMJ. 2012 May 04;344:e2856. (PMID: 22563098)
    • Accession Number:
      0 (Benzazepines)
      0 (Nicotinic Agonists)
      0 (Quinoxalines)
      01ZG3TPX31 (Bupropion)
      W6HS99O8ZO (Varenicline)
    • Publication Date:
      Date Created: 20141121 Date Completed: 20150804 Latest Revision: 20210109
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s11886-014-0554-8
    • Accession Number:
      25410148